ProfileGDS5678 / 1418422_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 20% 20% 20% 20% 20% 21% 20% 19% 20% 20% 20% 20% 20% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5076320
GSM967853U87-EV human glioblastoma xenograft - Control 22.4824820
GSM967854U87-EV human glioblastoma xenograft - Control 32.4780120
GSM967855U87-EV human glioblastoma xenograft - Control 42.4310220
GSM967856U87-EV human glioblastoma xenograft - Control 52.4216820
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5373720
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5233821
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4532720
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4403719
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.46520
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4589420
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4466620
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4727120
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4669520